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Author's View
Convincingly demonstrating the 
potency of the graft-vs-leukemia (GvL) 
effect, DLI has remained a cornerstone 
of therapy for hematologic relapse after 
HSCT since its initial discovery in 1990.1,2 
Subsequently, its widespread adoption 
unveiled a varied spectrum of clinical activ-
ity, with chronic myelogenous leukemia 
(CML) exhibiting an exquisite sensitivity.3
However, complications of DLI exist, 
including graft-vs.-host disease (GvHD) 
and the development of marrow aplasia. 
Efforts to divorce the morbidity of GvHD 
from an active GvL effect led to CD8+ 
T cell depletion from the donor graft. 
Infusion of CD8+-depleted (CD4+) DLI 
mitigated GvHD risk while preserving 
GvL activity in multiple settings.1,3,4
Mechanistic insights into DLI’s GvL 
effect stem mainly from studies of CD4+ 
DLI responses. Immune effector analyses 
uncovered a “footprint of response” occur-
ring both systemically in peripheral blood 
and locally within bone marrow, the site of 
disease (Fig. 1A). Systemic effects of DLI 
on both cellular and humoral immunity 
include increases both in T cell neogen-
esis and TCR repertoire diversity coupled 
with induction of B cell lymphocytosis and 
development of tumor-specific antibod-
ies.1,5 Moreover, effective DLI responses 
elicit innate immune involvement via sys-
temic TLR 8/9 activation.6 Finally, local 
expansion of preexisting tumor-specific 
marrow-resident CD8+ T cells after DLI 
further define the footprint of response 
distinguishing responders from nonre-
sponders in the wake of DLI treatment 
(Fig. 1A).5
Yet while downstream events correlat-
ing to DLI response have been well char-
acterized, the identification of biologic 
response predictors and understanding 
of the precise basis of DLI effectiveness 
remain elusive. To address this question, 
we exploited the historically clear response 
of CML to DLI and retrospectively ana-
lyzed marrow and peripheral blood sam-
ples from patients with relapsed CML after 
HSCT pre- and post-treatment with CD4+ 
DLI, all from the pre-imatinib era. Our 
study cohort of 22 responders and 7 non-
responders identified predictive markers of 
DLI response that elucidated a mechanis-
tic basis for DLI efficacy.7 Three key les-
sons derive from our study (Fig. 1B):
In Situ Characterization  
of Tumor and T Cells
We learned that in situ (marrow) T cell 
responses served as a more accurate indica-
tor of T cell immunity than those found 
in peripheral blood. Whereas no inter-
cohort differences in the temporal kinet-
ics of T cells manifested peripherally, we 
noted significantly different temporal 
patterns of CD8+ T cells infiltrating the 
marrow before and after DLI between the 
2 cohorts. These results suggest that local 
anti-tumor immune responses can be mod-
ulated systemically.
Identification of Novel  
Predictive Markers
The robust DLI response rate in CML 
also enabled us to pinpoint novel predic-
tive markers. Similar to others, we noted an 
inverse relationship between tumor burden 
and likelihood of response.1,3,8 Additionally, 
we found that an increased preexisting 
CD8+ T cell infiltrate correlated with 
response, even in patients with high disease 
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glean fresh insights into understanding and predicting effective anti-leukemia immunity.
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burden. In fact, incorporation of pre-DLI 
“burden” of both tumor and CD8+ T cells 
in response prediction perfectly distin-
guished our cohort with 100% sensitiv-
ity/specificity. Thus, the pretreatment 
immunologic state of the marrow, specifi-
cally preexisting CD8+ T cell infiltrates, 
emerged as a strong novel predictor of DLI 
response.
T Cell Exhaustion and 
Outstanding Questions
Cancers employ a barrage of immu-
noevasive strategies including T cell 
exhaustion—a dysfunctional state tran-
scriptionally distinct from anergy or 
senescence that is induced by chronic 
antigen exposure and marked by loss 
of effector and proliferative functions.9 
Transcriptional profiling of infiltrat-
ing CD3+ T cells revealed enrichment of 
exhaustion gene sets in responders before 
DLI and reversal of discrete exhaustion 
modules after therapy. These data strongly 
implicate this key pathway as a potential 
marker and mechanism of DLI respon-
siveness in relapsed CML after HSCT. 
Intriguingly, the clinical debut of anti-
PD1/PDL1 antibodies that may reverse T 
cell exhaustion suggests their use in lieu of 
DLI to promote GvL responses after allo-
geneic HSCT.
The involvement of T cell exhaus-
tion in predicting DLI response suggests 
effector failure of an anti-tumor immune 
response wherein DLI responders harbor a 
reservoir of infiltrating anti-tumor CD8+ 
T cells that have presumably already 
encountered CML tumor antigens (thus 
are exhausted). Given that these T cells 
have already achieved tumor specific-
ity, immunological “help” in the form of 
CD4+ T cells may be sufficient to rein-
vigorate a dormant anti-tumor response.
Of course, many questions persist. 
Our small, though well-defined, cohort 
should be expanded to determine appli-
cability to other hematologic malignan-
cies. More importantly, what occurs in the 
nonresponder’s tumor milieu (Fig. 1B)? 
Our data argue that the tumor microevi-
ronment of nonresponders harbors very 
few preexisting CD8+ T cells that lack 
phenotypic evidence of prior strong anti-
genic activation. Hence, these T cells are 
perhaps incapable of mounting a specific 
and potent anti-tumor response. Infusions 
of alternate donor grafts, perhaps con-
taining activated CD8+ T cells, could be 
considered for these patients.3 Increasing 
the graft cell dose is another possibil-
ity, and risk-adapted strategies target-
ing minimal residual disease states may 
improve DLI efficacy for this population 
by taking advantage of a lower tumor bur-
den.3 Finally, given the failure of effector 
immunity in responders, it is tempting to 
speculate an upstream failure of priming 
consistent with reduced T cell infiltrates 
in those without response. Such a scenario 
may be particularly amenable to multi-
epitope tumor vaccination strategies.10
Nevertheless, future delineation of 
immunoevasive maneuvers deployed by 
leukemias resistant to DLI may prove 
feasible with the use of next-generation 
sequencing and T cell profiling technolo-
gies. Concordantly, the mechanisms driv-
ing DLI efficacy may prove quite relevant 
Figure 1. signatures of DLi therapy. A “footprint of response” exists downstream of DLi therapy that distinguishes responders from nonresponders (A) 
Comprising immunostimulatory benefits in both adaptive and innate immunity, this footprint elucidates the diverse consequences of DLi; however, 
studies to detect these signals have not been generally designed to predict the likelihood of benefit. (B) on the other hand, detailed characterization of 
pre-DLi in situ tumor and t cell infiltrates identifies novel predictive markers of DLi responsiveness. in addition, t cell exhaustion is uncovered as a poten-
tial mechanism of efficacy. outstanding questions include further definition of the mechanisms driving DLi resistance in the nonresponding population.
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to other adoptive cell transfer therapies 
that promise anti-leukemia potential. 
DLI, then, has become a familiar face in 
the treatment arsenal against leukemic 
relapse whose study remains informative 
today.
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